Genentech scientist wins Kavli Prize in Neuroscience

Awarded for outstanding achievement in understanding the brain and nervous system

Richard Scheller, executive vice president, research and early development (gRED) at Genentech, a subsidiary of Swiss pharmaceutical firm Roche Group, has won the 2010 Kavli Prize in Neuroscience, which is awarded for outstanding achievement in advancing our knowledge and understanding of the brain and nervous system.

The Kavli Prizes, presented every two years in Oslo, Norway in cooperation with the Norwegian Academy of Science and Letters, recognise scientists for their seminal advances in astrophysics, nanoscience and neuroscience.

Scheller shares this year’s neuroscience prize, along with its cash award of US$1m, with James Rothman, professor and chairman of cell biology at Yale University, and Thomas Sudhof, professor of molecular and cellular physiology at Stanford University.

Scheller is donating his proceeds to the Wildlife Conservation Network, a San Francisco Bay Area-based organisation dedicated to protecting endangered species and preserving their natural habitats.

Scheller is responsible for overseeing Genentech's research, drug discovery, business development and early development activities. Prior to joining Genentech in 2001, he was professor of molecular and cellular physiology and biological science at Stanford University and an investigator with the Howard Hughes Medical Institute.

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Regulatory

Rheumatoid arthritis – sarilumab

Not all patients respond well to or tolerate TNF-alpha inhibitors, and an alternative strategy might be to treat with a drug against the interleukin-6 receptor alpha
Research & Development

Almac Discovery in ubiquitin specific protease collaboration with Genentech

Almac Discovery’s novel, potent and selective small molecule inhibitors will be the starting point for a two-year joint research programme
Manufacturing

Genentech to expand Hillsboro facility in Oregon, US

Will bring up to 100 new jobs to the state
Research & Development

Phylogica enters into research and licensing agreement with Genentech

Perth, Australia-based company will receive an upfront payment of US$500,000
Subscribe now